يعرض 51 - 60 نتائج من 1,846 نتيجة بحث عن '"Ruslan, M"', وقت الاستعلام: 1.10s تنقيح النتائج
  1. 51
    دورية أكاديمية
  2. 52
    دورية أكاديمية

    المساهمون: Авторы заявляют об отсутствии финансирования исследования.

    المصدر: Complex Issues of Cardiovascular Diseases; Том 12, № 4 (2023); 149-162 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 12, № 4 (2023); 149-162 ; 2587-9537 ; 2306-1278

    وصف الملف: application/pdf

    العلاقة: https://www.nii-kpssz.com/jour/article/view/1359/827Test; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1359/1387Test; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1359/1388Test; Kirk R, Dipchand AI, Rosenthal DN, Addonizio L, Burch M, Chrisant M, Dubin A, Everitt M, Gajarski R, Mertens L, Miyamoto S, Morales D, Pahl E, Shaddy R, Towbin J, Weintraub R. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant. 2014;33(9):888-909. doi:10.1016/j.healun.2014.06.002.; Абарова А.А., Малик В.И., Турмова Е.П. Особенности развития сердечной недостаточности у детей. International journal of professional science. 2022; (11-1): 80-85.; Senekovič Kojc T, Marčun Varda N. Novel Biomarkers of Heart Failure in Pediatrics. Children (Basel). 2022;9(5):740. doi:10.3390/children9050740.; Российское кардиологическое общество (РКО) . Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083; Агеев Ф.Т., Овчинников А.Г. Диастолическая сердечная недостаточность: 20 лет спустя. Актуальные вопросы патогенеза, диагностики и лечения сердечной недостаточности с сохраненной ФВ ЛЖ. Кардиология. 2023;63(3):3-12. doi:10.18087/cardio.2023.3.n2376; Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698-717. doi:10.1038/s41569-020-0381-0.; Шарипов А., Алимов А., Усманов Р., Расулов А., Шорахмедов, Ш. Диагностическое значение натрийуретического пептида при сердечной недостаточности у детей с врожденными пороками сердца . in Library. 2023; 1(1): 267–271.; Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2. doi:10.1186/s13036-017-0093-0.; Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18-25. doi:10.1016/j.peptides.2018.05.012.; Kiess A, Green J, Willenberg A, Ceglarek U, Dähnert I, Jurkutat A, Körner A, Hiemisch A, Kiess W, Vogel M. Age-Dependent Reference Values for hs-Troponin T and NT-proBNP and Determining Factors in a Cohort of Healthy Children (The LIFE Child Study). Pediatr Cardiol. 2022;43(5):1071-1083. doi:10.1007/s00246-022-02827-x.; Albers S, Mir T, Haddad M, Läer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clinical Chemistry and Laboratory Medicine (CCLM). 2006;44(1): 80-85. doi:10.1515/CCLM.2006.016; Pervez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Høiseth AD, Myhre PL, Røysland R, Lyngbakken MN, Omland T, Røsjø H. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018;23(7):654-663. doi:10.1080/1354750X.2018.1474258; Çavuşoğlu Y, Alper AT, Altay H, Çelik A, Demirkan B, Güvenç TS, Küçükoğlu MS, Nalbantgil S, Özdemir M, Özin B, Sayın T, Yıldırımtürk Ö, Yılmaz MB, Zorkun C. Natriuretic Peptides in Clinical Practice. Anatol J Cardiol. 2019;21(1):1-40. doi:10.14744/AnatolJCardiol.2019.55623.; Omran F, Kyrou I, Osman F, Lim VG, Randeva HS, Chatha K. Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. Int J Mol Sci. 2022;23(10):5680. doi:10.3390/ijms23105680.; Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med. 2017;27(2):123-133. doi:10.1016/j.tcm.2016.07.005.; Bobillo-Perez S, Girona-Alarcon M, Corniero P, Sole-Ribalta A, Balaguer M, Esteban E, Valls A, Jordan I, Cambra FJ. Pro-atrial natriuretic peptide and pro-adrenomedullin before cardiac surgery in children. Can we predict the future? PLoS One. 2020;15(7):e0236377. doi:10.1371/journal.pone.0236377.; Kotby AA, Taman KH, Sedky HT, Habeeb NM, El-Hadidi ES, Yosseif HS. Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload. J Paediatr Child Health. 2013;49(1):43-47. doi:10.1111/jpc.12012.; Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. Physiol Rev. 2019;99(4):1765-1817. doi:10.1152/physrev.00022.2018.; Чаулин А.М., Дупляков Д.В. Высокочувствительные сердечные тропонины: циркадные ритмы. Кардиоваскулярная терапия и профилактика. 2021;20(1):2639. doi:10.15829/1728-8800-2021-2639; Халиков А.А., Кузнецов К.О., Искужина Л.Р., Халикова Л.В. Судебно-медицинские аспекты внезапной аутопсия-отрицательной сердечной смерти. Судебно-медицинская экспертиза. 2021;64(3):59 63. doi:10.17116/sudmed20216403159; Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Mustonen H, Porela P, Harjola VP. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10(8):772-779. doi:10.1016/j.ejheart.2008.06.009.; Torre M, Jarolim P. Cardiac troponin assays in the management of heart failure. Clin Chim Acta 2015; 441: 92–98. doi:10.1016/j.cca.2014.12.027.; Uner A, Doğan M, Ay M, Acar C. The evaluation of serum N-terminal prohormone brain-type natriuretic peptide, troponin-I, and high-sensitivity C-reactive protein levels in children with congenital heart disease. Hum Exp Toxicol. 2014;33(11):1158-1166. doi:10.1177/0960327113514097.; Zhou FJ, Zhou CY, Tian YJ, Xiao AJ, Li PL, Wang YH, Jia JW. Diagnostic value of analysis of H-FABP, NT-proBNP, and cTnI in heart function in children with congenital heart disease and pneumonia. Eur Rev Med Pharmacol Sci. 2014;18(10):1513-1516.; Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol. 2009;104(9):1280-1284. doi:10.1016/j.amjcard.2009.06.046.; Sugimoto M, Ota K, Kajihama A, Nakau K, Manabe H, Kajino H. Volume overload and pressure overload due to left-to-right shunt-induced myo- cardial injury. Evaluation using a highly sensitive cardiac Troponin-I assay in children with congenital heart disease. Circ J 2011; 75: 2213–2219.; Kotby AA, Abd Al Aziz MM, Husseiny AH, Al-Fahham MM. Detection of Early Myocardial Injury in Children with Ventricular Septal Defect Using Cardiac Troponin I and Two-Dimensional Speckle Tracking Echocardiography. Pediatr Cardiol. 2020;41(8):1548-1558. doi:10.1007/s00246-020-02410-2.; Kayali S, Ertugrul I, Yoldas T, Kaya O, Ozgür S, Orün UA, Karademir S. Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease? Pediatr Cardiol. 2018;39(4):718-725. doi:10.1007/s00246-018-1811-1.; Cheung YF, Li VW, Lai CT, Shin VY, Keung W, Cheuk DK, Kwong A, Li RA, Chan GC. Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment. Pediatr Res. 2021;89(5):1245-1252. doi:10.1038/s41390-020-1049-5.; Алиева А.М., Байкова И.Е., Резник Е.В., Т.В. Пинчук, Л.М. Шнахова, Р.К. Валиев, М.Н. Сарыев, А.М. Рахаев, И.В. Ковтюх, И.Г. Никитин. Сердечный белок, связывающий жирные кислоты, — перспективный биологический маркер при сердечной недостаточности. РМЖ. Медицинское обозрение. 2022;6(1):5-11. doi:10.32364/2587-6821-2022-6-1-5-11.; Jaiswal A, Vamne A, Verma MK, Doctor B. H-FABP as a diagnostic marker for early detection of young myocardial infarction among Indians. Bioinformation. 2022;18(6):506-512. doi:10.6026/97320630018506.; Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. doi:10.1016/bs.acc.2016.09.002.; Rezar R, Jirak P, Gschwandtner M, Derler R, Felder TK, Haslinger M, Kopp K, Seelmaier C, Granitz C, Hoppe UC, Lichtenauer M. Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far? J Clin Med. 2020;9(1):164. doi:10.3390/jcm9010164.; Russell TM, Richardson DR. The good Samaritan glutathione-S-transferase P1: An evolving relationship in nitric oxide metabolism mediated by the direct interactions between multiple effector molecules. Redox Biol. 2023;59:102568. doi:10.1016/j.redox.2022.102568.; Andrukhova O, Salama M, Rosenhek R, Gmeiner M, Perkmann T, Steindl J, Aharinejad S. Serum glutathione S-transferase P1 1 in prediction of cardiac function. J Card Fail.;18(3):253-61. doi:10.1016/j.cardfail.2011.11.003; Tripaydonis A, Conyers R, Elliott DA. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling. Clin Pharmacol Ther. 2019;105(3):614-624. doi:10.1002/cpt.1311.; Яфарова А.А., Киселев А.Р., Шептулина А.Ф., Драпкина О.М. Современные представления о роли галанинергической системы в патогенезе сердечной недостаточности и ремоделирования миокарда. Кардиоваскулярная терапия и профилактика. 2023;22(5):3546. doi:10.15829/1728-8800-2023-3546; Алиева АМ, Байкова ИЕ, Кисляков ВА, Гасанова ЭТ, Алмазова ИИ, Пинчук ТВ, Федулаев ЮН, Жбанов ИВ, Перевертов ВА, Ковтюх ИВ, Никитин ИГ, Резник ЕВ. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью.Терапевтический архив. 2019;91(9):145-149. doi:10.26442/00403660.2019.09.000226; Saleh N, Khattab A, Rizk M, Salem S, Abo-Haded H. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study. BMC Paediatr 2020; 20: 537. doi:10.1186/s12887- 020-02427-9.; Gocer H, Günday M, Ünal M. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases. Clin Ter. 2019;170(4):267-271. doi:10.7417/CT.2019.2146.; McGinn C, Casey FA, Watson C, Morrison L. Paediatric heart failure - understanding the pathophysiology and the current role of cardiac biomarkers in clinical practice. Cardiol Young. 2023;33(4):503-513. doi:10.1017/S1047951123000331.; Kotby AA, Youssef OI, Elmaraghy MO, El Sharkawy OS. Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity. Pediatr Cardiol. 2017;38(1):95-102. doi:10.1007/s00246-016-1488-2.; Фетисова В.И., Намитоков А.М., Гилевич И.В., Космачева Е.Д. Растворимый белок подавления онкогенности (sST2) в качестве возможного биомаркера у пациентов с острым коронарным синдромом. Южно-Российский журнал терапевтической практики. 2023;4(2):7-17. doi:10.21886/2712-8156-2023-4-2-7-17; Bi J, Garg V, Yates AR. Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill. Biomolecules. 2021;11(2):166. doi:10.3390/biom11020166.; Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:754499. doi:10.3389/fcvm.2021.754499.; Aimo A, Georgiopoulos G, Senni M, Emdin M. Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues. Eur J Heart Fail. 2020;22(9):1598-1599. doi:10.1002/ejhf.1977.; Ragusa R, Prontera C, Di Molfetta A, Cabiati M, Masotti S, Del Ry S, Amodeo A, Trivella MG, Clerico A, Caselli C. Time-course of circulating cardiac and inflammatory biomarkers after Ventricular Assist Device implantation: Comparison between paediatric and adult patients. Clin Chim Acta. 2018;486:88-93. doi:10.1016/j.cca.2018.07.036.; Hauser JA, Demyanets S, Rusai K, Goritschan C, Weber M, Panesar D, Rindler L, Taylor AM, Marculescu R, Burch M, Wojta J, Michel-Behnke I. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart. 2016;102(20):1633-1639. doi:10.1136/heartjnl-2016-309460.; van den Bosch E, Bossers SSM, Kamphuis VP, Boersma E, Roos-Hesselink JW, Breur JMPJ, Ten Harkel ADJ, Kapusta L, Bartelds B, Roest AAW, Kuipers IM, Blom NA, Koopman LP, Helbing WA. Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort. J Am Heart Assoc. 2021;10(5):e015022. doi:10.1161/JAHA.119.015022.; Ghelani SJ, Opotowsky AR, Harrild DM, Powell AJ, Azcue N, Ahmad S, Clair NS, Bradwin G, Rathod RH. Characterization of Circulating and Urinary Biomarkers in the Fontan Circulation and Their Correlation With Cardiac Imaging. Am J Cardiol. 2022;162:177-183. doi:10.1016/j.amjcard.2021.08.06.; Халиков АА, Кильдюшов ЕМ, Кузнецов КО, Искужина ЛР, Рахматуллина ГР. Использование микроРНК с целью определения давности наступления смерти: обзор. Судебная медицина. 2021;7(3):132-138. doi:10.17816/fm412; Berezin AE. Circulating Biomarkers in Heart Failure. Adv Exp Med Biol. 2018;1067:89-108. doi:10.1007/5584_2017_140.; Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17(4):405-15. doi:10.1002/ejhf.244.; Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, Sucharov CC. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. J Heart Lung Transplant. 2015;34(5):724-33. doi:10.1016/j.healun.2015.01.979.; Liu Y, Guan S, Xu H, Zhang N, Huang M, Liu Z. Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis. Front Cardiovasc Med. 2023;10:1175174. doi:10.3389/fcvm.2023.1175174.; Алиева А.М., Резник Е.В., Пинчук Т.В., Аракелян Р.А., Валиев Р.К., Рахаев А.М., Тихомирова А.С., Никитин И.Г. Фактор дифференцировки роста-15 (GDF-15) как биологический маркер при сердечной недостаточности. Архивъ внутренней медицины. 2023;13(1):14-23. doi:10.20514/2226-6704-2023-13-1-14-23.; Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12(12):1309-16. doi:10.1093/eurjhf/hfq151.; Cheung CL, Tan KCB, Au PCM, Li GHY, Cheung BMY. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine. 2019;41:85-90. doi:10.1016/j.ebiom.2019.02.021.; Zhou XJ, Zhang X, Zhang J, Zhou L, Zhou TT, Zhang JW. Diagnostic value of growth differentiation factor-15 and β2-microglobulin in children with congenital heart disease combined with chronic heart failure and its relationship with cardiac function. Eur Rev Med Pharmacol Sci. 2020;24(15):8096-8103. doi:10.26355/eurrev_202008_22494.; Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA Clin. 2015;4:69-75. doi:10.1016/j.bbacli.2015.07.002.; Chatterjee NA, Singh JP. Novel Interventional Therapies to Modulate the Autonomic Tone in Heart Failure. JACC Heart Fail. 2015;3(10):786-802. doi:10.1016/j.jchf.2015.05.008.; Алиева АМ, Теплова НВ, Воронкова КВ, Пинчук ТВ, Валиев РК, Шнахова ЛМ, Рахаев АМ, Никитин ИГ. Адреномедуллин – биологический маркер сердечной недостаточности: обзор современной литературы. CardioСоматика. 2022;13(1):64-69. doi:10.17816/22217185.2022.1.201472; Hala A., Amal A.M. Study of adrenomedullin in children with heart failure. Alex. J. Pediatr. 2005;19:17.; Кремнева Л.В. Значение копептина для диагностики инфаркта миокарда. Российский кардиологический журнал. 2017;(11):93-97. doi:10.15829/1560-4071-2017-11-93-97; Karki K.B., Towbin J.A., Philip R.R., Harrell C., Tadphale S., Shah S., Saini A. Copeptin: A novel biomarker in pediatric heart failure due to cardiomyopathies. Circulation. 2019;140:A11217; Elhewala AA, Sanad M, Soliman AM, Sami MM, Ahmed AA. Matrix metalloproteinase-9 in pediatric rheumatic heart disease with and without heart failure. Biomed Rep. 2021;14(1):4. doi:10.3892/br.2020.1380.; Демко И.В., Собко Е.А., Соловьева И.А., Крапошина А.Ю., Гордеева Н.В., Аникин Д.А. Роль окислительного стресса в патофизиологии кардиоваскулярной патологии. Вестник современной клинической медицины. 2022;1: 107-117. doi:10.20969/VSKM.2022.15(1).107-117.; Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-2438. doi:10.2174/1381612811319130011.; Krantz M, Klipp E. Moonlighting proteins - an approach to systematize the concept. In Silico Biol. 2020;14(1-2):71-83. doi:10.3233/ISB-190473.; Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93(2):185-198. doi:10.1189/jlb.0712349.; Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM, Drum CL. Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. Biomedicines. 2023;11(3):917. doi:10.3390/biomedicines11030917; Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006;152(1):94-101. doi:10.1016/j.ahj.2005.09.020.; El-Alameey I.R., Mahmoud R.A., Kairy S.A., Medany E.A. Significance of myeloperoxidase in the onset of cardiovascular disease among obese children and adolescents. Biomed. Pharmacol. J. 2019;12:1647–1659. doi:10.13005/bpj/1795.; https://www.nii-kpssz.com/jour/article/view/1359Test

  3. 53
    دورية أكاديمية

    المساهمون: Авторы заявляют об отсутствии финансирования исследования.

    المصدر: Complex Issues of Cardiovascular Diseases; Том 12, № 3 (2023); 27-37 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 12, № 3 (2023); 27-37 ; 2587-9537 ; 2306-1278

    وصف الملف: application/pdf

    العلاقة: https://www.nii-kpssz.com/jour/article/view/1325/805Test; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1325/1324Test; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1325/1325Test; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1325/1326Test; Otto C.M., Nishimura R.A., Bonow R.O., Carabello B.A., Erwin J.P. 3rd, Gentile F., Jneid H., Krieger E.V., Mack M., McLeod C., O'Gara P.T., Rigolin V.H., Sundt T.M. 3rd, Thompson A., Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5). doi:10.1161/CIR.0000000000000932; Ross D.N. Surgical reconstruction of the aortic valve. Lancet. 1963;1(7281):571-4. doi:10.1016/s0140-6736(63)92687-4; Love C.S., Love J.W. The Autogenous Tissue Heart Valve: Current Status. J Cardiac Surgery. 1991;6(4):499-507. doi:10.1111/j.1540-8191.1991.tb00351.x; Subramanian S., Tikhomirov V., Bharati S., ElZein C., Roberson D., Ilbawi M.N. Relationship of Normal Aortic Valve Cusp Dimensions: A Tool to Optimize Cusp Reconstruction Valvuloplasty. Seminars in Thoracic and Cardiovascular Surgery. 2016;28(2):521-527. doi:10.1053/j.semtcvs.2015.08.005; Ozaki S., Kawase I., Yamashita H., Uchida S., Nozawa Y., Takatoh M., Hagiwara S. A total of 404 cases of aortic valve reconstruction with glutaraldehyde-treated autologous pericardium. The Journal of Thoracic and Cardiovascular Surgery. 2014;147(1):301-306. doi:10.1016/j.jtcvs.2012.11.012; Park T., Kim S., Cho Y., Park K., Park J.S., Kim M.H, Kim Y.D. Asymmetric aortic valve is related to development of eccentric aortic regurgitation in patients with tricuspid aortic valve. Echocardiography. 2019;36(6):1035-1040. doi:10.1111/echo.14374; Joseph L., Krishnaswamy A., Tuzcu E.M., Sonny A., Ozkan A., Svensson L.G., Griffin B.P., Thomas J., Kapadia S.R. Relation of cuspal asymmetry to development of aortic stenosis in adults with tricuspid aortic valves. J Heart Valve Dis. 2014;23(4):395-405; Джиоева О. Н., Максимова О. А., Рогожкина Е. А., Драпкина О. М. Особенности протокола трансторакального эхокардиографического исследования у пациентов с ожирением. Российский кардиологический журнал. 2022;27(12):5243. doi:10.15829/1560-4071-2022-5243.; Комаров Р.Н., Катков А.И., Одинокова С.Н. Современные анатомические представления о строении корня аорты с точки зрения практикующего хирурга. Кардиология и сердечно-сосудистая хирургия. 2019;12(5):433-440 doi:10.17116/kardio201912051433; Комаров Р.Н., Яснопольская Н.В., Чернявский С.В., Катков А.И. Протезирование аортального клапана аутоперикардом по методике Ozaki. Кардиология и сердечно-сосудистая хирургия. 2017;10(5):72 73. doi:10.17116/kardio201710572-73; Sarrafzadeh-Ghadimi N., Ghalichi F., Niroomand-Oscuii H., Fatouraee N. Design of an aortic polymeric valve with asymmetric leaflets and evaluation of its performance by finite element method. Computers in Biology and Medicine. 2022;145:105440. doi:10.1016/j.compbiomed.2022.105440; Joseph L, Krishnaswamy A., Tuzcu E.M., Sonny A., Ozkan A., Svensson L.G., Griffin B.P., Thomas J., Kapadia S.R. Relation of cuspal asymmetry to development of aortic stenosis in adults with tricuspid aortic valves. J Heart Valve Dis. 2014;23(4):395-405.; Ozaki S., Kawase I., Yamashita H., Uchida S., Nozawa Y., Matsuyama T., Takatoh M., Hagiwara S. Aortic valve reconstruction using self-developed aortic valve plasty system in aortic valve disease. Interactive CardioVascular and Thoracic Surgery. 2011;12(4):550-553. doi:10.1510/icvts.2010.253682; Ozaki S., Kawase I., Yamashita H., Uchida S., Takatoh M., Kiyohara N. Midterm outcomes after aortic valve neocuspidization with glutaraldehyde-treated autologous pericardium. The Journal of Thoracic and Cardiovascular Surgery. 2018;155(6):2379-2387. doi:10.1016/j.jtcvs.2018.01.087; Krane M., Boehm J., Prinzing A., Ziegelmueller J., Holfeld J., Lange R. Excellent Hemodynamic Performance After Aortic Valve Neocuspidization Using Autologous Pericardium. The Annals of Thoracic Surgery. 2021;111(1):126-133. doi:10.1016/j.athoracsur.2020.04.108; Benedetto U., Sinha S., Dimagli A., Dixon L., Stoica S., Cocomello L., Quarto C., Angelini G.D., Dandekar U., Caputo M. Aortic valve neocuspidization with autologous pericardium in adult patients: UK experience and meta-analytic comparison with other aortic valve substitutes. European Journal of Cardio-Thoracic Surgery. 2021;60(1):34-46. doi:10.1093/ejcts/ezaa472; Ozaki S., Kawase I., Yamashita H., Uchida S., Takatoh M., Hagiwara S., Kiyohara N. Aortic Valve Reconstruction Using Autologous Pericardium for Aortic Stenosis. Circ J. 2015;79(7):1504-1510. doi:10.1253/circj.CJ-14-1092; Reuthebuch O., Koechlin L., Schurr U., Grapow M., Fassl J., Eckstein F.S. Aortic valve replacement using autologous pericardium: single centre experience with the Ozaki technique. Swiss Med Wkly. 2018;148(56). doi:10.4414/smw.2018.14591; Iida Y., Fujii S., Akiyama S., Sawa S. Early and mid-term results of isolated aortic valve neocuspidization in patients with aortic stenosis. Gen Thorac Cardiovasc Surg. 2018;66(11):648-652. doi:10.1007/s11748-018-0976-0; Iida Y., Sawa S., Fujii S., Shimizu H. Aortic valve neocuspidization in patients under 65 years old. Gen Thorac Cardiovasc Surg. 2020;68(8):780-784. doi:10.1007/s11748-020-01302-9; Pirola S., Mastroiacovo G., Arlati F.G., Mostardini G., Bonomi A., Penza E., Polvani G. Single Center Five Years’ Experience of Ozaki Procedure: Midterm Follow-up. The Annals of Thoracic Surgery. 2021;111(6):1937-1943. doi:10.1016/j.athoracsur.2020.08.039; Koechlin L., Schurr U., Miazza J., Imhof S., Maurer M., Erb J., Gahl B., Santer D., Berdajs D., Eckstein F.S., Reuthebuch O. Echocardiographic and Clinical Follow-up After Aortic Valve Neocuspidization Using Autologous Pericardium. World J Surg. 2020;44(9):3175-3181. doi:10.1007/s00268-020-05588-x; Mylonas K.S., Tasoudis P.T., Pavlopoulos D., Kanakis M., Stavridis G.T., Avgerinos D.V. Aortic valve neocuspidization using the Ozaki technique: A meta-analysis of reconstructed patient-level data. American Heart Journal. 2023;255:1-11. doi:10.1016/j.ahj.2022.09.003; Unai S., Ozaki S., Johnston D.R., Saito T., Rajeswaran J., Svensson L.G., Blackstone E.H., Pettersson G.B. Aortic Valve Reconstruction With Autologous Pericardium Versus a Bioprosthesis: The Ozaki Procedure in Perspective. JAHA. 2023;12(2):e027391. doi:10.1161/JAHA.122.027391; https://www.nii-kpssz.com/jour/article/view/1325Test

  4. 54
    دورية أكاديمية
  5. 55
    دورية أكاديمية
  6. 56
    دورية أكاديمية
  7. 57
    دورية أكاديمية
  8. 58
    دورية أكاديمية
  9. 59
    دورية أكاديمية
  10. 60
    دورية أكاديمية

    المؤلفون: Ruslan M. Kliuchnyk

    المصدر: Vìsnik Unìversitetu ìmenì Alʹfreda Nobelâ: Serìâ Pedagogìka ì Psihologiâ, Vol 2, Iss 22, Pp 201-211 (2021)

    وصف الملف: electronic resource